Hepatitis C virus resistance to the new direct-acting antivirals.
about
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineRetinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo.Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.Treatment of hepatitis C with new fixed dose combinations.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.Synthesis and biological evaluation of tricyclic matrinic derivatives as a class of novel anti-HCV agents.Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.Opposite Effects of Two Human ATG10 Isoforms on Replication of a HCV Sub-genomic Replicon Are Mediated via Regulating Autophagy Flux in Zebrafish.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients
P2860
Q28076883-992A996C-D939-48B9-86A4-577AF1836130Q36214085-4B897BD4-42A4-4991-B69E-9E39014FEB5AQ39380623-D2F17943-CCF9-4A0B-A6B8-1F2AC8A1B580Q39411801-7411EDAB-0F02-4308-A7A4-32515722B578Q40101596-1C6DE808-9A3D-484B-8675-3E7DEF12DD43Q40104295-716988C3-B9CC-48B4-ABCD-391F849CD1FAQ40148071-CA99EBF4-0612-41B6-8256-73F85453966FQ40285894-8B9B6E4C-1F95-4470-A68D-E9379FB8BE2AQ41921724-49CFA29A-795C-4F6A-86EB-8864BFC44E12Q42719904-AC7D4A29-602A-4983-A3CA-E99E48B9D593Q47274792-BEB0BC15-20B7-42E9-8FFE-19D3AC8E09E0Q55100149-49EAA851-B66E-4366-8313-AAC93CD8A242Q55280981-3618B44E-2D35-4DEA-86E8-A957A716E830Q58780610-88284E3C-A250-43A8-B557-F9826B5A667C
P2860
Hepatitis C virus resistance to the new direct-acting antivirals.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Hepatitis C virus resistance to the new direct-acting antivirals.
@en
type
label
Hepatitis C virus resistance to the new direct-acting antivirals.
@en
prefLabel
Hepatitis C virus resistance to the new direct-acting antivirals.
@en
P2860
P1476
Hepatitis C virus resistance to the new direct-acting antivirals.
@en
P2093
Isabella Esposito
Julieta Trinks
P2860
P304
P356
10.1080/17425255.2016.1209484
P407
P577
2016-07-06T00:00:00Z